ADVANCING THE SCIENTIFIC METHOD

Biomedical science and biotechnology are at an exciting and potentially transformative moment:

• NIH Statement on catalyzing the development of NAMs – a $400M innovation program announced on February 1st, 2024.

• FDA Modernization Act – a major update to biomedical regulatory policy, which CCS helped advocate for.

• Rapid acceleration in synthetic and simulation biology – including in silico (A.I.), in vitro, and in chemico models.

We believe a new paradigm of human-relevant R&D is fundamental to developing the next-generation of cures for patients and families. Our goal is to help accelerate this change.

DRIVING INNOVATION

In producing our first Innovation Landscape, the Center for Contemporary Sciences (CCS) evaluated more than 150 companies and organizations working with human-relevant and animal-free technologies for biomedical research and drug development.

* CCS holds no compensatory or monetary connections to any of the entities shown here